The total return over the past 12 months is +11.37% vs. +16.94% for the S&P 500. So far it's up -15.24% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +11.37% | +52.01% | +44.41% | +41.50% | +10.51% | N/A |
| Total Return CAGR | +11.37% | +52.01% | +44.41% | +41.50% | +10.51% | N/A |
| Revenue CAGR | +149.04% | N/A | N/A | N/A | +38.29% | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Madrigal Pharmaceuticals, Inc. (MDGL)
| Year | Start price | End price | MDGL Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $582.34 | $493.62 | (15.24%) | +14.51% | (29.75%) |
| 2025 | $308.57 | $582.34 | +88.72% | +17.72% | +71.00% |
| 2024 | $231.38 | $308.57 | +33.36% | +24.89% | +8.47% |
| 2023 | $290.25 | $231.38 | (20.28%) | +26.19% | (46.47%) |
| 2022 | $84.74 | $290.25 | +242.52% | (18.17%) | +260.69% |
| 2021 | $111.17 | $84.74 | (23.77%) | +28.74% | (52.51%) |
| 2020 | $91.11 | $111.17 | +22.02% | +18.37% | +3.65% |
| 2019 | $112.72 | $91.11 | (19.17%) | +31.22% | (50.39%) |
| 2018 | $91.79 | $112.72 | +22.80% | (4.56%) | +27.36% |
| 2017 | $14.90 | $91.79 | +516.04% | +21.70% | +494.34% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
